Accepted for Publication: January 23, 2020.
Corresponding Author: Raymond F. Anton, MD, Addiction Sciences Division, Department of Psychiatry and Behavioral Sciences, Medical University of South Carolina, 67 President St, MSC 861, Charleston, SC 29425 (antonr@musc.edu).
Published Online: March 9, 2020. doi:10.1001/jamainternmed.2020.0249
Author Contributions: Drs Anton and Hoffman had full access to all of the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis.
Study concept and design: Anton.
Acquisition, analysis, or interpretation of data: All authors.
Drafting of the manuscript: Anton, Book, Bristol.
Critical revision of the manuscript for important intellectual content: Anton, Latham, Voronin, Book, Hoffman, Prisciandaro.
Statistical analysis: Anton, Hoffman, Prisciandaro.
Obtained funding: Anton.
Administrative, technical, or material support: Anton, Latham, Voronin, Book, Prisciandaro, Bristol.
Study supervision: Anton, Book, Prisciandaro.
Conflict of Interest Disclosures: Dr Anton reported receiving grants from the National Institute on Alcohol Abuse and Alcoholism during the conduct of the study; receiving grants and consulting fees from Laboratorio Farmaceutico CT; receiving consulting fees from Alkermes, Allergan, Indivior, Insys, Life Epigenetics, XenoPort (Arbor Pharmaceuticals), and Alcohol Clinical Trials Initiative (ACTIVE) outside the submitted work; and serving as a member and chair of ACTIVE, which was partially supported by Alkermes, Amygdala Neurosciences, Arbor Pharmaceuticals, Ethypharm, Indivior, Lundbeck, Mitsubishi, and Otsuka. Dr Book reported receiving grants from the National Institutes of Health during the conduct of the study. Dr Prisciandaro reported receiving grants and consulting fees from Farmaceutico Italiano and consulting fees from Laboratorio Farmaceutico CT outside the submitted work. No other disclosures were reported.
Funding/Support: Funding for this work was provided by the National Institute on Alcohol Abuse and Alcoholism (grant R01AA022364).
Role of the Funder/Sponsor: The National Institute on Alcohol Abuse and Alcoholism had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.
Data Sharing Statement: See Supplement 3.
Additional Contributions: Mark Ghent, BA, Department of Psychiatry and Behavioral Sciences, Medical University of South Carolina, assisted in data collection, and Patrick Randall, PhD, Department of Psychiatry and Behavioral Sciences, Medical University of South Carolina, assisted in initial power analyses and analytic planning and were compensated for their work.
1.Grant
BF , Chou
SP , Saha
TD ,
et al. Prevalence of 12-month alcohol use, high-risk drinking, and
DSM-IV alcohol use disorder in the United States, 2001-2002 to 2012-2013: results from the National Epidemiologic Survey on Alcohol and Related Conditions.
JAMA Psychiatry. 2017;74(9):911-923. doi:
10.1001/jamapsychiatry.2017.2161PubMedGoogle ScholarCrossref 4.Schuckit
MA , Smith
TL , Daeppen
JB ,
et al. Clinical relevance of the distinction between alcohol dependence with and without a physiological component.
Am J Psychiatry. 1998;155(6):733-740.
PubMedGoogle Scholar 5.Caetano
R , Clark
CL , Greenfield
TK . Prevalence, trends, and incidence of alcohol withdrawal symptoms: analysis of general population and clinical samples.
Alcohol Health Res World. 1998;22(1):73-79.
PubMedGoogle Scholar 10.O’Malley
SS , Krishnan-Sarin
S , Farren
C , Sinha
R , Kreek
MJ . Naltrexone decreases craving and alcohol self-administration in alcohol-dependent subjects and activates the hypothalamo-pituitary-adrenocortical axis.
Psychopharmacology (Berl). 2002;160(1):19-29. doi:
10.1007/s002130100919PubMedGoogle ScholarCrossref 14.Schacht
JP , Randall
PK , Latham
PK ,
et al. Predictors of naltrexone response in a randomized trial: reward-related brain activation,
OPRM1 genotype, and smoking status.
Neuropsychopharmacology. 2017;42(13):2640-2653. doi:
10.1038/npp.2017.74PubMedGoogle ScholarCrossref 17.Littleton
J . Neurochemical mechanisms underlying alcohol withdrawal.
Alcohol Health Res World. 1998;22(1):13-24.
PubMedGoogle Scholar 19.Schacht
JP , Anton
RF , McNamara
PJ , Im
Y , King
AC . The dopamine transporter VNTR polymorphism moderates the relationship between acute response to alcohol and future alcohol use disorder symptoms.
Addict Biol. 2019;24(5):1109-1118. doi:
10.1111/adb.12676PubMedGoogle ScholarCrossref 20.Addolorato
G , Leggio
L , Hopf
FW , Diana
M , Bonci
A . Novel therapeutic strategies for alcohol and drug addiction: focus on GABA, ion channels and transcranial magnetic stimulation.
Neuropsychopharmacology. 2012;37(1):163-177. doi:
10.1038/npp.2011.216PubMedGoogle ScholarCrossref 23.Zamponi
GW , Striessnig
J , Koschak
A , Dolphin
AC . The physiology, pathology, and pharmacology of voltage-gated calcium channels and their future therapeutic potential.
Pharmacol Rev. 2015;67(4):821-870. doi:
10.1124/pr.114.009654PubMedGoogle ScholarCrossref 26.Yoshizumi
M , Parker
RA , Eisenach
JC , Hayashida
K . Gabapentin inhibits γ-amino butyric acid release in the locus coeruleus but not in the spinal dorsal horn after peripheral nerve injury in rats.
Anesthesiology. 2012;116(6):1347-1353. doi:
10.1097/ALN.0b013e318254e6fdPubMedGoogle ScholarCrossref 38.Falk
DE , Ryan
ML , Fertig
JB ,
et al; National Institute on Alcohol Abuse and Alcoholism Clinical Investigations Group (NCIG) Study Group. Gabapentin enacarbil extended-release for alcohol use disorder: a randomized, double-blind, placebo-controlled, multisite trial assessing efficacy and safety.
Alcohol Clin Exp Res. 2019;43(1):158-169.
PubMedGoogle Scholar 39.Goldberg
JF , Burdick
KE . Cognitive side effects of anticonvulsants.
J Clin Psychiatry. 2001;62(suppl 14):27-33.
PubMedGoogle Scholar 43.First
MB , Spitzer
RL , Gibbon
M , Williams
JBW . Structured Clinical Interview for DSM-IV Axis I Disorders—Patient Edition. Version. 2.0. New York, NY: New York State Psychiatric Institute; 1997.
46.Pettinati
HM , Weiss
RD , Miller
WR , Donovan
D , Ernst
DB , Rounsaville
BJ . Medical Management Treatment Manual: A Clinical Research Guide for Medically Trained Clinicians Providing Pharmacotherapy as Part of the Treatment for Alcohol Dependence. Bethesda, MD: National Institute on Alcohol Abuse and Alcoholism; 2004.
47.Anton
RF , O’Malley
SS , Ciraulo
DA ,
et al; COMBINE Study Research Group. Combined pharmacotherapies and behavioral interventions for alcohol dependence: the COMBINE study: a randomized controlled trial.
JAMA. 2006;295(17):2003-2017. doi:
10.1001/jama.295.17.2003PubMedGoogle ScholarCrossref 48.Johnson
BA , Ait-Daoud
N , Roache
JD . The COMBINE SAFTEE: a structured instrument for collecting adverse events adapted for clinical studies in the alcoholism field.
J Stud Alcohol Suppl. 2005;(15):157-167. doi:
10.15288/jsas.2005.s15.157PubMedGoogle Scholar 49.Pittman
B , Gueorguieva
R , Krupitsky
E , Rudenko
AA , Flannery
BA , Krystal
JH . Multidimensionality of the Alcohol Withdrawal Symptom Checklist: a factor analysis of the Alcohol Withdrawal Symptom Checklist and CIWA-Ar.
Alcohol Clin Exp Res. 2007;31(4):612-618. doi:
10.1111/j.1530-0277.2007.00345.xPubMedGoogle Scholar 54.Helander
A , Wielders
JP , Jeppsson
JO ,
et al; IFCC Working Group on Standardization of Carbohydrate-Deficient Transferrin (WG-CDT). Toward standardization of carbohydrate-deficient transferrin (CDT) measurements: II. performance of a laboratory network running the HPLC candidate reference measurement procedure and evaluation of a candidate reference material.
Clin Chem Lab Med. 2010;48(11):1585-1592. doi:
10.1515/CCLM.2010.322PubMedGoogle ScholarCrossref 55.American Psychiatric Association. Handbook of Psychiatric Measures. Washington, DC: American Psychiatric Association; 2000.
57.Center for Drug Evaluation and Research. Alcoholism: Developing Drugs for Treatment. Guidance for Industry. Silver Spring, MD: Center for Drug Evaluation and Research; 2015.
58.Anton
RF , Latham
PK , Voronin
KE ,
et al. Nicotine-use/smoking is associated with the efficacy of naltrexone in the treatment of alcohol dependence.
Alcohol Clin Exp Res. 2018;42(4):751-760. doi:
10.1111/acer.13601PubMedGoogle ScholarCrossref 60.Anton
RF , Lieber
C , Tabakoff
B ; CDTect Study Group. Carbohydrate-deficient transferrin and gamma-glutamyltransferase for the detection and monitoring of alcohol use: results from a multisite study.
Alcohol Clin Exp Res. 2002;26(8):1215-1222. doi:
10.1111/j.1530-0277.2002.tb02658.xPubMedGoogle Scholar 63.Leggio
L , Kenna
GA , Swift
RM . New developments for the pharmacological treatment of alcohol withdrawal syndrome. a focus on non-benzodiazepine GABAergic medications.
Prog Neuropsychopharmacol Biol Psychiatry. 2008;32(5):1106-1117. doi:
10.1016/j.pnpbp.2007.09.021PubMedGoogle ScholarCrossref 64.Griffin
WC
III , Haun
HL , Hazelbaker
CL , Ramachandra
VS , Becker
HC . Increased extracellular glutamate in the nucleus accumbens promotes excessive ethanol drinking in ethanol dependent mice.
Neuropsychopharmacology. 2014;39(3):707-717. doi:
10.1038/npp.2013.256PubMedGoogle ScholarCrossref